Cantor Fitzgerald Forecasts MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($1.55) per share for the year. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.45) per share.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. During the same period in the prior year, the company posted ($0.57) EPS. The business’s revenue was up 89.4% compared to the same quarter last year.

A number of other research firms have also weighed in on MIRM. Leerink Partners increased their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Citigroup increased their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Robert W. Baird raised their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.10.

Mirum Pharmaceuticals Trading Down 2.6 %

NASDAQ:MIRM opened at $46.72 on Thursday. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $48.89. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -23.13 and a beta of 0.98. The business has a fifty day moving average of $43.65 and a 200-day moving average of $41.40. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors have recently modified their holdings of MIRM. Amalgamated Bank grew its holdings in shares of Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $521,000. ProShare Advisors LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $213,000. Marshall Wace LLP lifted its position in shares of Mirum Pharmaceuticals by 35.9% during the 2nd quarter. Marshall Wace LLP now owns 20,520 shares of the company’s stock worth $702,000 after buying an additional 5,420 shares during the period. Finally, Squarepoint Ops LLC lifted its position in shares of Mirum Pharmaceuticals by 63.4% during the 2nd quarter. Squarepoint Ops LLC now owns 67,421 shares of the company’s stock worth $2,305,000 after buying an additional 26,154 shares during the period.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joanne Quan sold 6,969 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $45.86, for a total value of $319,598.34. Following the sale, the insider now directly owns 5,649 shares in the company, valued at $259,063.14. The trade was a 55.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,706 shares of company stock valued at $875,697 in the last 90 days. 22.87% of the stock is currently owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.